Malta - Tiếng Anh - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - carbidopa, levodopa - tablet - carbidopa 10.8 mg levodopa 100 mg - anti-parkinson drugs

Malta - Tiếng Anh - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - carbidopa, levodopa - tablet - carbidopa 27 mg levodopa 100 mg - anti-parkinson drugs

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

oceanside pharmaceuticals - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh) - carbidopa anhydrous 25 mg - carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. carbidopa is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. carbidopa is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication. carbidopa is used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. however, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from the addition of c

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg - tablet, uncoated - excipient ingredients: crospovidone; quinoline yellow aluminium lake; microcrystalline cellulose; magnesium stearate; pregelatinised maize starch - apo-levodopa/carbidopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. apo-levodopa/carbidopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

american health packaging - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - carbidopa and levodopa extended-release tablets are indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa extended-release tablets. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa extended-release tablets. carbidopa and levodopa extended-release tablets may be administered concomitantly with the manufacturer's recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hcl) (see precautions, drug interactions). carbidopa and levodopa extended-release tablets are contraindicated in patients with known hypersensitivity to any component of this drug, and in patients with narrow-angle glaucoma.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - carbidopa and levodopa tablets, usp are indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. carbidopa allows patients treated for parkinson's disease to use much lower doses of levodopa. some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets, usp. this is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa tablets. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa tablets. carbidopa and levodo

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

mayne pharma inc - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 10 mg - carbidopa and levodopa tablets usp are indicated in the treatment of parkinson's disease post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. carbidopa allows patients treated for parkinson's disease to use much lower doses of levodopa. some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets usp. this is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa. carbidopa and levodopa may be administe

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - carbidopa and levodopa tablets, usp are indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. carbidopa allows patients treated for parkinson's disease to use much lower doses of levodopa. some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets, usp. this is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa tablets. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa tablets. carbidopa and levodo

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - carbidopa and levodopa tablets are indicated in the treatment of parkinson's disease post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. carbidopa allows patients treated for parkinson's disease to use much lower doses of levodopa. some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets. this is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa. carbidopa and levodopa may be administered conc

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - carbidopa and levodopa extended-release tablets are indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa extended-release tablets. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa extended-release tablets. carbidopa and levodopa extended-release tablets may be administered concomitantly with the manufacturer's recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hcl) (see precautions, drug interactions). carbidopa and levodopa extended-release tablets are contraindicated in patients with known hypersensitivity to any component of this drug, and in patients with narrow-angle glaucoma.